id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S12708 R47948 |
Bjørk (Valproate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2022 | Diagnosis of intellectual disability (ID): mild ID (F70), moderate ID (F71), severe ID (F72), and profound ID (F73) (between 6.1 and 7.9 years old) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
7.97 [5.07;12.52] C excluded (control group) |
64/2,421 27/7,950 | 91 | 2,421 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12519 R47161 |
Bjørk (Valproate) (Controls unexposed NOS) (Mixed indications), 2022 | Diagnosis of intellectual disability (ID): mild ID (F70), moderate ID (F71), severe ID (F72), and profound ID (F73) (between 6.1 and 7.9 years old) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) excluded | Adjustment: Yes |
4.77 [3.73;6.10] excluded (control group) |
64/2,421 16,384/4,463,879 | 16,448 | 2,421 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12707 R47945 |
Bjørk (Valproate) (Controls unexposed, sick) (Mixed indications), 2022 | Diagnosis of intellectual disability (ID): mild ID (F70), moderate ID (F71), severe ID (F72), and profound ID (F73) (between 6.1 and 7.9 years old) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No Controls: epilepsy indication | 4.20 [3.11;5.66] C | 64/2,421 139/21,634 | 203 | 2,421 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9414 R33006 |
Meador (Valproate), 2013 | IQ <70 (DAS) (at 6 years old) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: Yes | 7.90 [0.37;168.31] C | 2/49 0/74 | 2 | 49 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9421 R33053 |
Titze (Valproate) (Controls unexposed, disease free), 2008 | Learning disability (IQ<70) (German versions of the revised Wechsler Intelligence Scales for children and for adults) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
19.40 [0.31;1195.39] C excluded (control group) |
0/3 0/49 | 0 | 3 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9422 R33054 |
Titze (Valproate) (Controls unexposed, sick), 2008 | Learning disability (IQ<70) (German versions of the revised Wechsler Intelligence Scales for children and for adults) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 1.53 [0.05;49.80] C | 0/3 1/13 | 1 | 3 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9428 R33107 |
Viinikainen (Valproate) b, 2006 | Full Scale IQ (FIQ) < 2SD (Wechsler Intelligence Scale for Children (WISC III)) | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No Matched | 5.95 [0.26;138.26] C | 2/13 0/13 | 2 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9429 R33117 |
Vinten (Valproate), 2005 | IQ score <69 (Wechsler Intelligence Scale for Children (WISC III)) (Aged between 6 and 16 years) | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: No | 3.47 [1.14;10.56] C | 9/41 6/80 | 15 | 41 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9401 R32945 |
Gaily (Valproate) (Controls unexposed, disease free), 2004 | Mental retardation (Verbal and nonverbal IQ <70) | 2nd and/or 3rd trimester | prospective cohort | unexposed, disease free | Adjustment: No | 3.83 [0.37;39.75] C | 1/13 3/141 | 4 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 6 studies | 4.15 [3.12;5.51] | 227 | 2,540 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Valproate) (Controls unexposed, sick) (Mixed indications; 2: Valproate; 3: Valproate) (Controls unexposed, sick; 4: Valproate) ; 5: Valproate; 6: Valproate) (Controls unexposed, disease free;
Asymetry test p-value = 0.7774 (by Egger's regression)
slope=1.4375 (0.0754); intercept=-0.0644 (0.2128); t=0.3024; p=0.7774
excluded 9421, 12708, 12519